Over the past year, several exciting new agents for the treatment of acute lymphoblastic leukemia (ALL) have been approved. In…
There have recently been a number of major drug approvals for the treatment of acute lymphoblastic leukemia (ALL). One such…
We need to understand the mechanisms of drug resistance in order to prevent it, in addition to informing subsequent treatment…
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage…
The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid…
The majority of patients with advanced systemic mastocytosis (AdvSM) exhibit D816V mutations of the KIT gene, which presents a promising…
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin was approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), the most…
Next-generation antibody-drug conjugates (ADCs) are demonstrating improved safety and tolerability compared with their predecessors. Speaking from the American Society of…
With the increasing complexity of clinical trials, the role of the Clinical Research Nurse (CRN) and the Clinical Nurse Specialist…
Staff within the NHS are very busy and work pressures can result in less time for communication between nurses. In…
What can be done to improve the experience of clinical trials for patients who participate? In this interview, recorded at…
Different NHS trusts work in different ways; what could be considered the best practice in one trust may not be…
The identification of novel therapeutic targets is essential for the improved treatment of hematological cancer, particularly due to the development…
We know that CAR T-cell therapy is effective in the treatment of chronic lymphocytic leukemia (CLL); however, a current limitation…
There is not a large amount of data available to allow clinicians to determine whether patients should remain on or…
Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial…
The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host…
The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert…
Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University…
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the…
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy…
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease…
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that…
This interview provides an exciting insight into the Translational Research Training in Hematology (TRTH) and the Clinical Research Training in…
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect…
Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus,…
There is currently an array of exciting clinical trials for mesothelioma, investigating cutting-edge treatments in large patient groups. Here, Dean…
There has been a vast increase in our understanding of the pathology of mesothelioma in the past 5 years, which…
Mesothelioma cases are on the rise, in both developed and developing countries. Thus, increased understanding of the underlying mechanisms of…
The first study illustrating the potential of MRI in the diagnosis of prostate cancer was published in 2006. Although there…
The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to…
Recent news reports have identified poorer outcomes in cancer patients from the UK compared with those in certain other European…
The take-home message from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, on MRI for prostate cancer diagnosis was…
The utilization of MRI for the diagnosis of prostate cancer in men at risk is relatively new. In this interview,…
Current practice in the UK requires urologists to refer patients with urological cancer to oncologists for treatment. In this interview,…
Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was…
There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical…
With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the…
The emergence of an effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is likely to have a paradigm-changing effect on…
Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III…
With the emergence of five novel immune checkpoint inhibitors for the treatment of urothelial carcinoma, the key question now arising…
A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data…
Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now,…
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma,…
Minimal residual disease (MRD) monitoring is a promising and controversial topic, with its increasing use in clinical trials being followed…
There was exciting new trial data for the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) from the American Society…
Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine…
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this…
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the pilot…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple…
Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can…
At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD,…
Copanlisib is a novel PI3K inhibitor, targeting both PI3K-? and PI3K-? isoforms in malignant B-cells. It was granted FDA approval…
Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify…
Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American…
Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is…
In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma…
An exciting new nurse-led rapid access lung cancer clinic has been started in Ceredigion, Wales. Here, the Clinical Nurse Specialist…
This years British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, presented a range of exciting data,…
The role of the nurse in the management and care of patients with cancer is essential one, which is evolving…
Robotic surgery equipment is notoriously expensive, limiting the number of hospitals and surgeons who can utilize this beneficial technology. In…
Where there was previously one primary manufacturer for robotic-assisted surgery machinery, there are now several newcomers on the block. Speaking…
Despite some forms of minimally invasive surgery being performed for some time, we are still lacking the analytical evidence that…
Robotic-assisted thoracic surgery can be combined with other techniques and utilized for a wide range of procedures. Here, Joel Dunning,…
Robotic-assisted surgery is an exciting, innovative area, which is growing and becoming more widespread. Here, Joel Dunning, PhD, FRCS, of…
This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this…
Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL).…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Immune & Combination Therapies Will be Important for Years Because of…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Adverse Effects of Venetoclax and Ibrutinib Only 1 in 50 Patients…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about Drugs to Use if One has Cancer or Clots…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses CLARITY Trial Limitations; No Control Group Extrapolated onto the FLAIR Trial…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Diagnostic Criteria for Thrombotic Thrombocytopenic Purpura One needs less than…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Positive Data for RR-CLL Patients Able to see MRD Negativity at…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Highlights from MDS and Nonmalignant Hematology New drugs for MDS:…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses The CLARITY Trial Lead by Dr. Hillmen Feasibility study that looked…
Angela Fleischman MD PhD UC Irvine discusses JAK Inhibitors are a Central Theme in MPN Lots of JAK Inhibitors being…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Rituximab Maintenance for Follicular Lymphoma CAR-T Trial…
Angela Fleischman MD PhD UC Irvine discusses Disease Managing Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations associated with Myeloid Malignancies;…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Echelon-1 Data Showed Modified Progression Free Survival…
Angela Fleischman MD PhD UC Irvine discusses Distinguishing Between Clonal Disorder & a Germ-Line Mutation Clonal disorder is a hematologic…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and…
Angela Fleischman MD PhD UC Irvine discusses Preventing Progress of MPN Presently this area is limited and needs to be…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates on PRIMA Study Progression Free Survival…
Angela Fleischman MD PhD UC Irvine discusses MPN (Myeloproliferative Neoplasm) & CHIP New phenomenon in aging individuals with mutations associated…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses how CAR-T Therapies will Dominate in 2018…
Angela Fleischman MD PhD UC Irvine discusses Disease Modifying Agents on the Horizon for MPN Hope to impact, intervene, &…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates Retrospective Analysis Looked At Rituximab Maintenance…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
In this Velocity Vlog activity, Dr. Richard S. Finn of the UCLA Geffen School of Medicine, provides a brief overview…
Filanesib is a novel agent that has previously shown clinical activity in pretreated multiple myeloma (MM) patients. In this interview,…
Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, gives us an overview of the GEM-Pembresid trial (NCT02636010),…
VCD (bortezomib, cyclophosphamide and dexamethasone) is an effective chemotherapy combination commonly used for the treatment of newly diagnosed multiple myeloma…
The results of the Phase III MURANO trial (NCT02005471) were important to address a number of unanswered questions surrounding the…
Now that hematological oncologists have an arsenal of novel single agents, the natural next step is to determine the best…
With the increasing use of immunotherapy, methods of response testing need to be rigorous and comparable. However, as explained here…
There are many areas of uncertainty surround immunotherapy, which require further exploration in the coming years. Speaking from the British…
Now that there is a range of immunotherapies available, the next frontier to explore is immunotherapy combination regimens. In this…
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University…
Tumor mutational burden (TMB) is emerging as a promising predictive biomarker for lung cancer immunotherapy response. Here, Fred Hirsch, MD,…
With the great promise that immunotherapy holds, there are hopes that it will revolutionize the treatment of lung cancer. Here,…
With exciting data for immuno-oncology in lung cancer, there is much anticipation for what 2018 holds. In this interview, Solange…
Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology…
After many negative trial results for non-small cell lung cancer (NSCLC) therapies for some time, the field is now evolving…
Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst,…
Data from the Phase III MURANO study (NCT02005471) is a hot topic in the field of hematological oncology. The study…
Sequential triple-T therapy is a regimen consisting of tailored and targeted treatment aiming for total eradication of minimal residual disease…
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview,…
Over the past 10 years, there has been a massive expansion in the number and classes of treatments available for…
The last 5-10 years has been a very exciting time for the treatment of myeloid malignancies, with great advances in…
Presented by Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 1 of 3 of a symposium recorded…
Presented by Ajay K. Nooka, MD, MPH, FACP. Part 2 of 3 of a symposium recorded at an oncology specialty…
Presented by Ajay K. Nooka, MD, MPH, FACP; Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 3…
Data for non-chemotherapy-based treatments is increasing exponentially, with the presentations at the American Society of Hematology (ASH) 2017 Annual Meeting…
Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato,…
Data from recent studies indicate that PD-1 and PD-L1/PD-L2 mediate immune evasion in chronic lymphocytic leukemia (CLL), highlighting their importance…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about updates on Myelodysplastic syndrome and nonmalignant hemetology at MOASCs…
Angela Fleischman, MD, from UC Irvine joins us at MOASCs Spotlight On Hematology in Huntington Beach to discusses the updates…
Deepa Jeyakumar, MD, from UC Irvine Health discusses the Acute myeloid leukemia highlights from ASH 2017 at MOASCs Spotlight On®…
Elizabeth Brém, MD, from The Chao Comprehensive Cancer Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to…
Amrita Krishnan MD FACP of The Judy and Bernard Briskin Center for Multiple Myeloma Research discusses the updates at ASH…
Ann Eapen, MD, from UC-Irvine Department of Hematology and Oncology is presenting the CLARITY Trial (Bloodwise TAP Study) which looks…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health talks about trying to understand the role of CPX-351 and if can be…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health talks about, Midostaurin, the 1st new and approved AML drug in a long…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to…
Deepa Jeyakumar, MD, from UC Irvine Health discusses how IDH2 inhibitor for AML is effective with Relapsed Refractory disease and…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the diagnostic criteria for thrombotic thrombocytopenic purpura and how…
Deepa Jeyakumar, MD, from UC Irvine Health talks about 4 new drugs for acute myeloid leukemia including Midostaurin, Gemtuzumab, and…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research talks about the antibody drug conjugate…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the highlights from Myelodysplastic Syndrome (MDS) and nonmalignant hematology…
Venetoclax is approved for the treatment of relapsed/refractory del17p chronic lymphocytic leukemia (CLL) and has shown activity in patients following…
Ibrutinib is approved for all lines of therapy in chronic lymphocytic leukemia (CLL); however, front-line ibrutinib studies have primarily enrolled…
The rapidly changing landscape of NSCLC treatment has drastically improved outcomes for patients. In this interview, Yvonne Summers, BSc, MB…
Knowledge about the different subtypes of and mutations within NSCLC has increased dramatically in the past 10 years. Here, Yvonne…
Integrated healthcare is vital to provide the optimal care to cancer patients at all stages, from diagnosis to remission and…
Beating cancer takes more than good luck and a good doctor, a high-tech medical center and exotic drugs. It takes…
Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr.…
Dr. Khaldoun Almhanna, MD, MPH, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida…
The AJCC guidelines have incorporated several new features, Kenneth Wang, MD, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic,…
The exciting 100,000 Genomes Project has the potential to transform the way patients are cared for. Speaking from the American…
Stivarga (regorafenib) is an effective drug but not one that is easily tolerable. Howard Hochster, MD, talks to us about…
The 100,000 Genomes Project is an exciting NHS programme, which aims to sequence 100,000 genomes from patients with rare diseases…
Bloodwise’s Trials Acceleration Programme (TAP) aims to boost the number and speed of hematological oncology studies in the UK. Here,…
While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In…
The issue of smoking and lung cancer screening poses many questions. Speaking from the British Thoracic Oncology Group (BTOG) Annual…
It widely agreed that we need to identify better methods of detecting lung earlier. There has been great data suggesting…
Reducing the length of diagnostic pathways can increase the number treatment options available and enable better patient experiences. Here, Neal…
Prior to the evaluation of whether lung cancer screening should be adopted, its impact on patient survival must be thoroughly…
The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. Currently, the…
The National Optimal Lung Cancer Pathway (NOLCP) was a much-discussed topic at the British Thoracic Oncology Group (BTOG) Annual Conference…
Long waits for and between treatments, leading to worse outcomes for patients, are unacceptable. Improved care pathways are required to…
The 2017 National Lung Cancer Audit (NCLA) report launched at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held…
The findings of the National Lung Cancer Audit (NCLA) annual reports provide a means to identify where lung cancer care…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, hosted the launch of the latest National…
As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change.…
The landscape of NSCLC treatment is evolving rapidly. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from…
The British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK revealed the latest clinical updates on prostate…
Targeted therapy for prostate cancer is a promising field, which is set to grow in the coming year. Here, Robert…
The identification of effective systemic medications for prostate cancer has been relatively recent and this field is now making exciting…
At the 2018 Gastrointestinal Cancers Symposium, David Ilson, MD, PhD, from the Memorial Sloan Kettering Cancer Center talks about a…
The common discussion of where to start a patients dosage of regorafenib. Steven J. Cohen, MD, the Chief of the…
Determining the progression and the responses of Hepatocellular Carcinoma (HCC). Professor Andrew X. Zhu, MD, PhD from Harvard Medical School…
The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018…
Sudipto Mukherjee, MD from Cleveland Clinics discusses promising novel agents that can change the treatment landscape and FLT3 and IDH1…
Jonathan Gerber, MD from Levine Cancer Institute discusses hopeful for the FDA approval of the IDH1 inhibitor and new generation…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, had a record number of attendees, following…
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, we asked a number of experts…
There have been great improvements in radiotherapy (RT) services in the UK over the past 10 years; however, there is…
Radiotherapy (RT) services in England are being shaken up in a reorganization, which was a hot topic at the British…
Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology…
Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology…
Pharmacists are integral to providing and developing supportive care in cancer. In this interview, the essential roles of the pharmacist…
Supportive care for cancer is a relatively new area and is set to grow as the need for it increases.…
Supportive care for patients with cancer is becoming increasingly important, with advances in care meaning more people are surviving and…
Aaron Gerds, MD from Cleveland Clinics discusses new forms of interferon have improved side-effect profiles and pegylated interferon and ropeginterferon…
Sudipto Mukherjee, MD from Cleveland Clinics discusses personalized prediction model for Myelodysplastic Syndromes and certain mutations predict non-malignant conditions at…
Jonathan Gerber, MD from Levine Cancer Institute discusses new agents becoming available for the 1st time in decades and what…
Sudipto Mukherjee, MD from Cleveland Clinics discusses two areas that potentially cut down rehospitalizations and follow patients to be on…
Aaron Gerds, MD from Cleveland Clinics discusses patients showed symptomatic relief in Phase I Trial of Glasdegib and 35% of…
Jonathan Gerber, MD from Levine Cancer Institute discusses 9 out of 10 achieved remission with Hypomethylating agent and next phase…
Sudipto Mukherjee, MD from Cleveland Clinics discusses preliminary findings of unplanned hospital readmissions and conclusive data may identify patients to…
Aaron Gerds, MD from Cleveland Clinics discusses Phase 2 Trial of Glasdegib in myelofibrosis was not launched – due to…
Sudipto Mukherjee, MD from Cleveland Clinics discusses predicting multiple rehospitalizations after initial admission – subsets of patients who have advanced…
Jonathan Gerber, MD from Levine Cancer Institute discusses changed the strategy of chemotherapy and transplants and gentle upfront then the…
Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses new information for normal plasma cell biology and findings…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE + Sorafenib may change standard in HCC and if overall survival…
Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses real world outcomes for myeloma patients trial and phase…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the Regorafenib Dose Optimization Study (ReDOS) and how a…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses Checking for CEA in Metastatic Anal Cancer and how…
Aaron Gerds, MD from Cleveland Clinics discusses Glasdegib intended to be long-term goal for treating myelofibrosis and isolating the roots…
Aaron Gerds, MD from Cleveland Clinics discusses longer-lasting interferon being developed: Ropeginterferon and ongoing randomized trial in polycythemia vera at…
David Feltquate Head of Early Clinical Development at BRISTOL-MYERS SQUIBB discusses the the phase 1b/2 open-label study which will explore…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Safety and Advantages…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Patient Disqualifiers such…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses moving ONC201 from Phase 2…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the the Patient Enrollment for…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient…
Aaron Gerds, MD from Cleveland Clinics discusses results of Phase I trial in heavily pre-treated myelofibrosis and dysgeusia and muscle…
Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses results of randomized trial of ELd treatment and primary endpoint was…
Joshua Richter, MD from John Theurer Cancer Center discusses CAR-T Cell therapy as potential venue for multiple myeloma and bispecific…
Aaron Gerds, MD from Cleveland Clinics discusses phase I-II trial of Glasdegib in myelofibrosis and that Glasdegib is a Hedgehog…
Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses ELOQUENT-2 study in Japanese patients safety was consistent with patients in…
Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342: A bispecific T cell engager that attaches to CD38…
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses FDA approval of several CAR-T Cell therapies and hope to make…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses new cancer research technologies in recent years and access new information and…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses development of a predictive model of multiple myeloma patient outcomes and…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses baseline disease characteristics & diagnostic patterns for NDMM – observations over…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses blood biopsies instead of bone marrow and new findings from blood biopsy…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses center for prevention of progression of blood cancers and focused on precursor…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses survival and depth of response in African American and Non-AA patients…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses cases when cell free DNA is most beneficial and specific patient populations…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Connect® multiple myeloma patient registry and eventually pool data from Connect®…
Joshua Richter, MD from John Theurer Cancer Center discusses next step for Phase 1 GBR 1342 studies and identifying the…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses collaborators provide samples to Dana Farber Institute and large amount of samples…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses limitations of blood biopsy and that one must have enough circulating DNA…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the first phase 3 trial of a new…
Joshua Richter, MD from John Theurer Cancer Center discusses inclusion and exclusion criteria of GBR 1342 and the trial designed…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses on how to improve the prediction of progression of multiple myeloma at…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses data shows safety of drugs for clinicians & academia…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib doing patterns and the data presented for appropriate dosing of…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses advantages of blood biopsy and how blood draw is comfortable and convenient…
Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342 studies in phase 1 and search for the maximum…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses phase 2 trial of Dasatinib with Philadelphia Chromosome+ ALL and how…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses largest study on genomic smoldering Multiple Myeloma and 135 patients were studied…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the analysis from the randomized phase 3 Aspire…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses trial combines Daratumumab with Carfilzomib & Dexamethasone and the…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses poster #1 phase 2 study of Daratumumab+ CyBorD and the dose…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses cell free DNA sequencing and DNA is isolated in the bloodstream instead…
John M Burke, MD from Rocky Mountain Cancer Centers discusses further promising studies in 2018 – CAR-T cell therapy, Polatuzumab,…